Attorney Docket No.: 0492611-0505 (MIT 9991) Express Mail No.: EV 170393752 US Filed: September 22, 2003

1		<u>Claims</u>
2		
3	What is claimed is:	
. 4		
5	1.	A conjugate for use in targeting a drug to a tissue, wherein a digestive enzyme is
6		overexpressed in the extracellular space of the tissue, the conjugate comprising:
7		a polymeric carrier;
8		a drug molecule; and
9		a linker that includes a first end and a second end, wherein the polymeric carrier is
10		associated with the first end of the linker and the drug is associated with the second end
11		of the linker and wherein the linker includes a recognition segment that is cleaved when
12		the conjugate is exposed to the digestive enzyme.
13		
14	2.	The conjugate of claim 1 further comprising:
15		additional drug molecules; and
16		additional linkers, wherein each drug molecule is indirectly associated with the
17		polymeric carrier via one of the linkers and wherein each linker includes a recognition
18		segment that is cleaved when the conjugate is exposed to the digestive enzyme.
19		
20	3.	The conjugate of claim 1, wherein the polymeric carrier is hydrophilic, biocompatible
21		and biodegradable.
22		

The conjugate of claim 1, wherein the polymeric carrier is larger than the renal excretion 1 4. 2 limit. 3 The conjugate of claim 1, wherein the drug is a small molecule drug. 5. 4 5 The conjugate of claim 1, wherein the drug is a biomolecular drug. 6 6. 7 The conjugate of claim 1, wherein the recognition segment is an oligopeptide. 8 7. 9 The conjugate of claim 1, wherein the recognition segment is an oligosaccharide. 10 8. 11 The conjugate of claim 1, wherein the tissue is diseased. 12 9. 13 The conjugate of claim 9, wherein the tissue is a tumor. 14 10. 15 A pharmaceutical composition comprising a pharmaceutically acceptable excipient and 16 11. an effective amount of the conjugate of claim 1. 17 18 A method of preparing a conjugate for use in targeting a drug to a tissue, wherein the 19 12. tissue overexpresses a digestive enzyme, the method comprising: 20 providing a polymer carrier; 21

Attorney Docket No.: 0492611-0505 (MIT 9991) Express Mail

Express Mail No.: EV 170393752 US Filed: September 22, 2003

1		providing a drug molecule;
2		providing a linker that includes at least a first end and a second end, wherein the
3		linker includes a recognition segment that is cleaved when the conjugate is exposed to the
4		digestive enzyme;
5		associating the polymer carrier with the first end of the linker; and
6		associating the drug molecule with the second end of the linker.
7		
8	13.	A method of administering a drug to a patient, the method comprising steps of:
9		providing a patient;
10		providing a pharmaceutical composition that comprises a pharmaceutically
11		acceptable excipient and an effective amount of the conjugate of claim 1; and
12		administering the pharmaceutical composition to the patient.